Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Medical Industry Feature

Improving Outcomes in hATTR-PN: The Role of Vigilant Symptom Assessment

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

Tune in to hear expert insights on how we can improve the diagnosis of polyneuropathy of hereditary transthyretin-mediated amyloidosis.

  • Sponsored by

  • Overview

    The early diagnosis of hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN) is critical because it gives us the chance to offer interventions that could not only improve quality of life but also maximize the patient’s function.1-3 However, diagnosing hATTR polyneuropathy can be challenging because its symptoms often mimic those of other neuropathies, making it difficult to distinguish from more common conditions.4-7 Joining Dr Jennifer Caudle to discuss these diagnostic challenges, the progressive symptoms of hATTR-PN, and strategies for improving patient identification and diagnosis is Dr Thomas Brannagan, Director of both the Peripheral Neuropathy Center and the Columbia Neuropathy Research Center at Columbia University in New York.

    References:

    1. Planté-Bordeneuve V, Ferreira A, Lalu T, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007;69:693-698.
    2. Nativi-Nicolau JN, Karam C, Khella S, Maurer MS. Screening for ATTR amyloidosis in the clinic: Overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022;27:785-793.
    3. Lauppe R, Hansen JL, Fornwall A, et al. Healthcare resource use of patients with transthyretin amyloid cardiomyopathy. ESC Heart Fail. 2022;9(3):1636-1642. 
    4. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
    5. Conceição I, González‐Duarte A, Obici L, et al. “Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Sys. 2016;21:5-9. 
    6. Kapoor M, Rossor AM, Laura M, Reilly MM. Clinical presentation, diagnosis and treatment of TTR amyloidosis. J Neuromuscul Dis. 2019;6:189-199. 
    7. Gertz MA. Hereditary ATTR amyloidosis: Burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(7 Suppl):S107-S112.

    ©2024 AstraZeneca. All rights reserved. 
    US-93599 Last Updated 11/24

Schedule11 Dec 2024